Ipilimumab was approved by the FDA on March 25, 2011 for the treatment of unresectable or metastatic melanoma. Sales in 2015 were US$1.13 billion.
Ipilimumab is a monoclonal antibody that binds to cytotoxic T lymphocyte-associated antigen (CTLA-4) and prevents the binding of CTLA-4 to its ligands (CD80 and CD86). Blocking CTLA-4 can increase T Cell activity and proliferation ability.
Let us work together to protect precious health